{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'use is prohibited.', 'use is prohibited.', 'Topiramate', 'Must be receiving stable', 'Topiramate', 'Must be receiving stable', '(up to', 'treatment (including dose)', '(up to', 'treatment (including dose)', '200 mg/day)', 'for at least 4 weeks before', '200 mg/day)', 'for at least 4 weeks before', 'screening.', 'screening.', 'Guanfacine', 'Allowed, regardless of', 'Guanfacine', 'Allowed, regardless of', 'indication (ie, if prescribed', 'indication (ie, if prescribed', 'for tics or Tourette', 'for tics or Tourette', 'syndrome). Must be', 'syndrome). Must be', 'receiving stable treatment', 'receiving stable treatment', '(including dose) for at', '(including dose) for at', 'least 4 weeks before', 'least 4 weeks before', 'screening and no changes', 'screening and no changes', 'to dose or frequency are', 'to dose or frequency are', 'anticipated during the', 'anticipated during the', 'course of the study. If', 'course of the study. If', 'discontinuation of', 'discontinuation of', 'guanfacine is anticipated', 'guanfacine is anticipated', 'due to ineffectiveness.', 'due to ineffectiveness,', 'poor tolerability, or', 'poor tolerability, or', 'patient/caregiver', 'patient/caregiver', 'preference, discontinuation', 'preference, discontinuation', 'should occur 4 or more', 'should occur 4 or more', 'weeks prior to the', 'weeks prior to the', 'screening visit.', 'screening visit.', 'Clonidine', 'Allowed, regardless of', 'Clonidine', 'Allowed, regardless of', 'indication (ie, if prescribed', 'indication (ie, if prescribed', 'for tics or Tourette', 'for tics or Tourette', 'syndrome). Must be', 'syndrome). Must be', 'receiving stable treatment', 'receiving stable treatment', '(including dose) for at', '(including dose) for at', 'least 4 weeks before', 'least 4 weeks before', 'screening and no changes', 'screening and no changes', 'to dose or frequency are', 'to dose or frequency are', 'anticipated during the', 'anticipated during the', 'course of the study. If', 'course of the study. If', 'discontinuation of', 'discontinuation of', 'clonidine is anticipated due', 'clonidine is anticipated due', 'to ineffectiveness, poor', 'to ineffectiveness, poor', 'tolerability, or', 'tolerability, or', 'patient/caregiver', 'patient/caregiver', 'preference, discontinuation', 'preference, discontinuation', 'should occur 4 or more', 'should occur 4 or more', 'weeks prior to the', 'weeks prior to the', 'screening visit.', 'screening visit.', '191']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'Stimulants', 'Include amphetamine,', 'Stimulants', 'Include amphetamine,', 'methylphenidate, and', 'methylphenidate, and', 'lisdexamfetamine. Primary', 'lisdexamfetamine. Primary', 'use is for the treatment of', 'use is for the treatment of', 'ADHD; dosing must have', 'ADHD; dosing must have', 'been stable for at least 2', 'been stable for at least 2', 'weeks before screening', 'weeks before screening', 'and no changes to dose or', 'and no changes to dose or', 'frequency are anticipated', 'frequency are anticipated', 'during the course of the', 'during the course of the', 'study.', 'study.', 'SNRIs', 'Includes atomoxetine.', 'SNRIs', 'Includes atomoxetine.', 'Primary use is for the', 'Primary use is for the', 'treatment of ADHD;', 'treatment of ADHD;', 'dosing must have been', 'dosing must have been', 'stable for at least 4 weeks', 'stable for at least 4 weeks', 'before screening and no', 'before screening and no', 'changes to dose or', 'changes to dose or', 'frequency are anticipated', 'frequency are anticipated', 'during the course of the', 'during the course of the', 'study.', 'study.', 'Additional medications allowed with', 'Additional medications allowed with', 'preapproval from medical monitor', 'preapproval from medical monitor', 'Albuterol,', 'Asthma', 'Albuterol,', 'Asthma', 'levalbuterol', 'levalbuterol', 'Guaifenesin', 'Cold symptoms', 'Guaifenesin', 'Cold symptoms', 'Antihistamine', 'Allergies', 'Antihistamine', 'Allergies', 'S', 'S', 'Melatonin', 'Insomnia', 'Melatonin', 'Insomnia', 'Allowed strong CYP inhibitors', 'Allowed strong CYP inhibitors', 'Bupropion', 'Antidepressant', 'Bupropion', 'Antidepressant', '(aminoketone)', '(aminoketone)', 'Fluoxetine', 'Antidepressant (selective', 'Fluoxetine', 'Antidepressant (selective', 'serotonin reuptake', 'serotonin reuptake', 'inhibitor)', 'inhibitor)', 'Paroxetine', 'Antidepressant (selective', 'Paroxetine', 'Antidepressant (selective', 'serotonin reuptake', 'serotonin reuptake', 'inhibitor)', 'inhibitor)', 'a', 'The use of these medications will affect', 'a', 'The use of these medications will affect', 'the maximum daily dose of IMP, as shown', 'the maximum daily dose of IMP, as shown', 'in Table 2. ADHD=Attention-', 'in Table 2. ADHD=Attention-', '192']\n\n###\n\n", "completion": "END"}